Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens

Karin Jordan, Richard Gralla, Giada Rizzi, Kimia Kashef

Open source

DOI
10.1007/s00520-016-3304-1
Published
2016-06-22
Container
Supportive Care in Cancer
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00520-016-3304-1,
  title = {Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens},
  author = {Karin Jordan and Richard Gralla and Giada Rizzi and Kimia Kashef},
  year = {2016},
  journal = {Supportive Care in Cancer},
  doi = {10.1007/s00520-016-3304-1},
  url = {https://doi.org/10.1007/s00520-016-3304-1}
}

RIS

TY  - JOUR
TI  - Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens
AU  - Karin Jordan
AU  - Richard Gralla
AU  - Giada Rizzi
AU  - Kimia Kashef
PY  - 2016
JO  - Supportive Care in Cancer
DO  - 10.1007/s00520-016-3304-1
UR  - https://doi.org/10.1007/s00520-016-3304-1
ER  - 

APA

Jordan, K., Gralla, R., Rizzi, G., & Kashef, K. (2016). Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Supportive Care in Cancer. https://doi.org/10.1007/s00520-016-3304-1

Source records